Determined.
Passionate.
Driving change.

For those you care for

Focusing on the development of new drugs for the treatment of inflammatory diseases

Our mission

Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.

 

Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.

Upcoming events

No Events on The List at This Time

News

Temisis Therapeutics is proud to be nominated in the 2018 PRIX GALIEN – MEDSTARTUP!

Technology

Our main asset in dermatology, TEM1657, is a brand-new small molecule that shows similar efficacy as market reference corticosteroids at pre-clinical stage to remit psoriasis symptoms but without the common side effects that are associated.

1

Rapid efficacy

Symptoms are significantly reduced after the first application of TEM1657.

2

Complete remission of psoriasis symptoms

No erythema – Regulated desquamation – Normal skin thickness.

3

No side effect

No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.

icon-dataroom

Dataroom

Temisis is sharing latest non-confidential data about the development of TEM1657 with interested partners and potential investors.

Contact us

19 av de la Forêt de Haye,
54500 Vandœuvre-lès-Nancy
France
Tel.: +33 (0) 383 940 342
contact@temisis.com
www.temisis.com

icon-contact
X